pyrazines has been researched along with Primary Myelofibrosis in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Barbui, T; Barosi, G; Rambaldi, A | 1 |
| Barosi, G; Campanelli, R; Facchetti, F; Fisogni, S; Gattoni, E; Goldberg, J; Guglielmelli, P; Hoffman, R; Marchioli, R; Vannucchi, AM | 1 |
| Lacy, MQ; Tefferi, A | 1 |
| Auradé, F; Chaligné, R; Gastinne, T; Giraudier, S; Gonin, P; Lacout, C; Pisani, DF; Tulliez, M; Vainchenker, W; Villeval, JL; Wagner-Ballon, O | 1 |
| Battolla, B; Canestraro, M; Capodanno, A; Casini, A; Collecchi, P; Fazzi, R; Galimberti, S; Mattii, L; Orciuolo, E; Pacini, S; Petrini, M; Piaggi, S; Simi, P; Trombi, L; Veroni, F | 1 |
| Canestaro, M; Ciancia, E; Fazzi, R; Galimberti, S; Marasca, R; Petrini, M | 1 |
| Hussein, K; Lasho, T; Mesa, RA; Pardanani, A; Rivera, C; Tefferi, A; Verstovsek, S; Wu, W | 1 |
2 review(s) available for pyrazines and Primary Myelofibrosis
| Article | Year |
|---|---|
From palliation to epigenetic therapy in myelofibrosis.
Topics: Amino Acid Substitution; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Epigenesis, Genetic; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Janus Kinase 2; Mutation; Palliative Care; Primary Myelofibrosis; Pyrazines; Radiotherapy; Signal Transduction; Splenectomy; Transplantation, Homologous | 2008 |
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Primary Myelofibrosis; Protease Inhibitors; Pyrazines; Thalidomide | 2011 |
2 trial(s) available for pyrazines and Primary Myelofibrosis
| Article | Year |
|---|---|
Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bone Marrow; Boronic Acids; Bortezomib; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Primary Myelofibrosis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Risk; Salvage Therapy; Thrombocytopenia; Treatment Failure; Young Adult | 2010 |
Bortezomib therapy in myelofibrosis: a phase II clinical trial.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Primary Myelofibrosis; Pyrazines | 2008 |
4 other study(ies) available for pyrazines and Primary Myelofibrosis
| Article | Year |
|---|---|
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.
Topics: Animals; Boronic Acids; Bortezomib; Disease Models, Animal; Mice; NF-kappa B; Osteosclerosis; Primary Myelofibrosis; Protease Inhibitors; Pyrazines; Survival Rate; Thrombopoietin | 2007 |
PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression; Genes, Wilms Tumor; Humans; Leukemia, Megakaryoblastic, Acute; NF-kappaB-Inducing Kinase; Primary Myelofibrosis; Protease Inhibitors; Protein Serine-Threonine Kinases; Pyrazines | 2008 |
Bortezomib is able to reduce angiogenesis in half of patients affected by idiopathic myelofibrosis: an ex vivo study.
Topics: Boronic Acids; Bortezomib; Colony-Forming Units Assay; Female; Humans; Male; Middle Aged; Neovascularization, Pathologic; Primary Myelofibrosis; Pyrazines; Tissue Culture Techniques | 2008 |